Laboratorios AUNA, Área de Biología Molecular, Lima, Peru.
Centro de Investigación Básica y Translacional, AUNA IDEAS, Lima, Peru.
Front Public Health. 2024 Feb 12;11:1244662. doi: 10.3389/fpubh.2023.1244662. eCollection 2023.
In Peru, on 11 February 2023, the Ministry of Health registered 4 million patients infected with COVID-19 and around 219,260 deaths. In 2020, the SARS-CoV-2 virus was acquiring mutations that impacted the properties of transmissibility, infectivity, and immune evasion, leading to new lineages. In the present study, the frequency of COVID-19 variants was determined during 2021 and 2022 in patients treated in the AUNA healthcare network.
The methodology used to detect mutations and identify variants was the Allplex™ SARS-CoV-2 Variants Assay I, II, and VII kit RT-PCR. The frequency of variants was presented by epidemiological weeks.
In total, 544 positive samples were evaluated, where the Delta, Omicron, and Gamma variants were identified. The Delta variant was found in 242 (44.5%) patients between epidemiological weeks 39 and 52 in 2021. In the case of Gamma, it was observed in 8 (1.5%) patients at weeks 39, 41, 43, 45, and 46 of 2021. The Omicron variant was the most frequent with 289 (53.1%) patients during weeks 49 to 52 of 2021 and 1 to 22 of 2022. During weeks 1 through 22 of 2022, it was possible to discriminate between BA. 1 ( = 32) and BA.2 ( = 82).
The rapid identification of COVID-19 variants through the RT-PCR methodology contributes to timely epidemiological surveillance, as well as appropriate patient management.
2023 年 2 月 11 日，秘鲁卫生部登记了 400 万例 COVID-19 感染病例和约 219260 例死亡病例。2020 年，SARS-CoV-2 病毒发生突变，影响了其传播力、感染力和免疫逃逸能力，从而产生了新的谱系。本研究旨在确定 2021 年和 2022 年在 AUNA 医疗网络治疗的患者中 COVID-19 变异株的频率。
用于检测突变和识别变异株的方法是 Allplex™ SARS-CoV-2 Variants Assay I、II 和 VII RT-PCR 试剂盒。通过流行病学周来呈现变异株的频率。
共评估了 544 份阳性样本，其中鉴定出了 Delta、Omicron 和 Gamma 变异株。Delta 变异株于 2021 年第 39 至 52 周在 242 例（44.5%）患者中检出。Gamma 变异株于 2021 年第 39、41、43、45 和 46 周在 8 例（1.5%）患者中检出。Omicron 变异株是最常见的，于 2021 年第 49 至 52 周和 2022 年第 1 至 22 周期间有 289 例（53.1%）患者检出。在 2022 年第 1 至 22 周期间，能够区分 BA.1（ = 32）和 BA.2（ = 82）。
通过 RT-PCR 方法快速识别 COVID-19 变异株有助于及时进行流行病学监测，并对患者进行适当的管理。
